Doxazosin
As of the edition of 20 October 2026, Doxazosin is a small molecule: marketed, first approved in 1990 (ES); acts on ADRA1A, ADRA1B and ADRA1D.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1999
- Kind
- Small molecule
- Brand name
- Cardura
- First approved
- 1 November 1990 (ES)
- Approvals on record
- 8 in 3 regions
- Holder of the most recent approval
- Viatris; 3 holders in all
- Registered trials
- 33, 3 stopped early
- Disease areas
- Mental health; Chemically induced; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product6 company-target rows are on route B because of Doxazosin.
See the 6 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 2 | 0 | 2 |
| Phase 1 | 6 | 5 | 0 | 1 |
| Phase 2 | 11 | 8 | 1 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 8 | 8 | 0 | 0 |
| All trials | 33 |